UBS Downgrades Cano Health to Sell, Lowers Price Target to $3.75
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Andrew Mok has downgraded Cano Health (NYSE:CANO) from Neutral to Sell and significantly reduced the price target from $12 to $3.75.
November 17, 2023 | 3:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cano Health downgraded by UBS from Neutral to Sell, with a price target decrease from $12 to $3.75, indicating a bearish outlook.
The downgrade by a major analyst like UBS from Neutral to Sell, accompanied by a significant reduction in the price target, suggests a negative outlook on Cano Health's stock. This is likely to influence investor sentiment and could lead to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100